Press

FSD Pharma Inc. Provides Update on Spin-Out Plan, Announces Shareholder Meeting

Apr 14 • 4 min read

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is pleased to announce it intends to complete a spin-out transaction via a plan of arrangement (the “ Plan of Arrangement ”)…

PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules

Apr 14 • 3 min read

PharmAla Biotech Holdings Inc. (CSE:MDMA), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical-stage natural psychedelic drug development company, today announced the GMP release of MDMA capsules at the Metro Vancouver facility operated by Filament’s subsidiary Psilo…

PSYC Set to Relaunch Bonfire with “Psychedelics for Beginners” Online Course

Apr 14 • 6 min read

PSYC Corporation (OTC Pink Market: PSYC), parent company to Spotlight Media Corporation (“SMC” or the “wholly owned subsidiary”), a multimedia leader for all things psychedelics including the emerging medicinal psychedelics market sector, is pleased to provide shareholders with an update on its Bonfire community platform, which is scheduled to relaunch May 1st with several new features and…

Sunstone Therapies Announces Publication of Positive Data on Use of Psilocybin Therapy for Patients with Cancer and Major Depression Disorder, in JAMA Oncology

Apr 14 • 3 min read

Sunstone Therapies, a leader in the development of clinical trials and the delivery of psychedelic-assisted therapy in the medical setting, today announces the publication of positive phase 2 data, assessing the effect of psilocybin therapy for patients with cancer and major depression disorder (MDD), in JAMA Oncology. The publication is accessible here. Psilocybin therapy is an…

Numinus Launches New Website to Enhance its Client Experience

Apr 14 • 3 min read

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new client website at www.numinus.com as part of its branding strategy to align all wellness clinics under the Numinus brand. “Our new website serves as a key connection point to…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448